Long-term follow-up of cytogenetically normal CEBPA-mutated AML.

ABSTRACT:

Background

The aim of this study was to analyze the long-term survival of AML patients with CEBPA mutations.

Patients and methods

We investigated 88 AML patients with a median age of 61 years and (1) cytogenetically normal AML (CN-AML), (2) monoallelic (moCEBPA) or biallelic (biCEBPA) CEBPA mutation, and (3) intensive induction treatment. 60/88 patients have been described previously with a shorter follow-up.

Results

Median follow-up time was 9.8 years (95% CI: 9.4-10.1 years) compared to 3.2 and 5.2 years in our former analyses. Patients with biCEBPA mutations survived significantly longer compared to those with moCEBPA (median overall survival (OS) 9.6 years vs. 1.7 years, p = 0.008). Patients ≤ 60 years and biCEBPA mutations showed a favorable prognosis with a 10-y

SUBMITTER: Pastore F 

PROVIDER: S-EPMC4172831 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature